Lyna Soertidewi
Faculty of Medicine, University of Indonesia

Published : 2 Documents

Found 2 Documents

Plasmin for Enhanced Improvement in Acute Ischaemic Stroke: A Multicentre Randomized Placebo-Controlled Trial Misbach, Jusuf; Jannis, Jofizal; Kustiowati, Endang; Umbas, David Gunawan; Nurimaba, Nurjaman; Suratno, Suratno; Kotambunan, Siwi; Yamanie, Nizar; Soertidewi, Lyna; Octaviana, Fitri; Khosama, Herlyani
Journal of the Indonesian Medical Association Vol. 59 No. 5 May 2009
Publisher : Journal of the Indonesian Medical Association

Show Abstract | Download Original | Original Source | Check in Google Scholar


Plasmin® (rongshuan jiaonans) is a medicine from China - which has gone through a high technology of biochemical extraction - that has thrombolitic effect, fibrinolytic effect, anticoagulant, antiplatelet and anti-inflamation effect. The purpose of this study was to evaluate Plasmin® in acute ischemic stroke patients in a randomized, double-blind, placebo-controlled trial using some assessments of functional outcome and vascular as well as labarotary parameter such as Barthel Index (BI) and Modified Rankin Scale (MRS), mini mental state examination (MMSE), transcranial Doppler’s (TCD) performance, and measurement of blood analysis including fibrinogen level, INR, platelet aggregation, total cholesterol, HDL cholesterol, LDL cholesterol, and triglyceride level. An 84-day randomized double-blind placebo-controlled study was conducted. Participants were recruited from six academic hospitals that had been diagnosed as ischaemic stroke for the first time after 2 hours and before 2 weeks of onset. Patients were randomly assigned to plasmin® or placebo control (1:1 ratio). Sixty patients of ichaemic stroke who fulfilled inclusion criteria were enrolled in the study over 84 days period, with 44 participants completing the study (21 plasmin and 23 placebo). The increasing of BI score at 84th day compare to 14th day was significantly more in plasmin group than in placebo. Eighteen participants (85.7%) of plasmin showed improvement in MRS score, while in placebo group only 12 participants (52.2%) showed improvement (p =0.018). Motor strength of upper extremity was seen improving significantly in plasmin after 14 days of treatment compare to placebo, while lower extremity was significantly improved after 28 days of treatment. Administration of plasmin® in the acute ischaemic stroke patient between 2 hours and 2 weeks of onset showed significant improvement in motor strength, BI score, and MRS score. Further study with larger number of participants is recommended to confirm the benefit of plasmin® in management of acute ischaemic stroke.Keywords: acute ischaemic stroke, Barthel Index, Modified Rankin Scale, plasmin, randomized controlled trial
Profil Mortalitas Stroke Associated Pneumonia Tahun 2016-2017 Ritonga, Anna Mardiana; Syarif, Syahrizal; Soertidewi, Lyna
Jurnal Ilmu dan Teknologi Kesehatan Vol 6 No 2 (2019): Maret 2019
Publisher : Poltekkes Kemenkes Jakarta III

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (81.693 KB) | DOI: 10.32668/jitek.v6i2.172


Stroke associated pneumonia (SAP) is the most common complication after stroke and has a high mortality rate. SAP mortality profile among Neuro ICU patients has not been fully investigated. Knowledge of mortality profiles can help clinical decision making for patient management. The purpose of this study was to determine the mortality profile of SAP who were treated in the Neuro ICU National Brain Centre (NBC) Hospital. This was a retrospective cohort study of the patients were hospitalized in the Neuro ICU NBC Hospital, who were diagnosed with SAP during 2016-2017. Clinical and laboratory data and the patient's status during treatment are obtained from medical record data. A total of 197 stroke patients who were treated at the Neuro ICU NBC Hospital during 2016-2017, there were 130 (65.98%) patients diagnosed with SAP, with mortality during treatment of 77.7%. The highest SAP mortality was found in male patients (75%), in the age group ≥ 60 years (55.4%), GCS at admission ≤ 8 (88.3%), accompanied by hypertension (66.7%) and leukocytosis (74.8%). In bivariate analysis, the variables that were statistically significant (p <0.05) were hypertension, GCS, LoS, APACHE II score, and PMR.